NEW YORK and LEAMINGTON — Tilray Brands has announced a series of strategic expansion initiatives, highlighted by the acquisition of the Lyphe Group, a leading UK-based medical cannabis clinic and digital pharmacy platform.
The acquisition anchors Tilray Medical’s footprint in the European healthcare market and establishes the company's first fully vertically integrated medical platform. By bringing Lyphe under its umbrella, Tilray now directly combines its pharmaceutical-grade cannabis cultivation and manufacturing operations with clinical care, patient access, and digital dispensing services.
This integration capitalizes on an established and growing market footprint. To date, Lyphe Dispensary has distributed approximately 150,000 units, while Lyphe Clinic has treated over 16,000 patients.
To optimize supply chain operations, Tilray will leverage the sourcing capabilities, purchasing power, and established scale of its CC Pharma division to efficiently supply medications through the Lyphe platform, further fortifying its overall European distribution network.
Additionally, the digital pharmacy infrastructure accelerates Tilray’s existing capabilities in seamlessly dispensing both medical cannabis and traditional prescription medicines.
Positioning for U.S. Regulatory Shifts
Tilray is actively preparing for the anticipated rescheduling of medical cannabis in the United States, engaging directly with legislators and regulatory bodies as drug policy evolves.
As part of its U.S. operational strategy, the company is evaluating participation in the Center for Medicare and Medicaid Innovation (CMMI) pilot program. This move would allow Tilray to partner with Accountable Care Organizations (ACOs) and oncology practices to supply hemp-derived medical cannabis to underserved patients while gathering critical data on therapeutic outcomes.
Denise Faltischek, Chief Strategy Officer and Head of M&A for Tilray Brands, emphasized the company’s operational readiness for federal policy changes.
"Upon rescheduling, Tilray Medical is strategically positioned to participate in a U.S. regulated medical cannabis market, evidenced by our proven track record of operating at scale in highly-regulated medical cannabis markets globally, supported by our pharmaceutical quality systems, scientific expertise, and our ongoing commitment to education and clinical research," Faltischek stated. "We believe that rescheduling will occur in the near-term and, when it does, we are well-positioned to seize the opportunity."
